yep the competitors have 10-15 years of published data showing survival and reoperation rate with their products
this is what you will need for your product to be able to compete
why do you think the patch sales didnt take off as predicated
docs didnt think it was different form what they already had or were not prepared to pay more
Ann: DurAVR valve patient outcomes exceed expectations, page-51
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.20 |
Change
-0.200(1.09%) |
Mkt cap ! $349.8M | |||
| Open | High | Low | Value | Volume |
| $18.50 | $18.50 | $18.00 | $77.59K | 4.263K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 206 | $18.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.70 | 34 | 1 |
View Market Depth
| Last trade - 16.10pm 26/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |